CAPRICOR THERAPEUTICS, INC. - 8-K Filing

Capricor Therapeutics signed a lease for new headquarters in San Diego contingent on FDA approval by December 31, 2026. (Items: 1.01 of this Current Report on Form 8-K is hereby incorporated in this Item 2)

SEC EDGAR ·

Tickers: $CAPR

Read the full article at SEC EDGAR

More Regulatory news